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Abstract 
Context 
Availability of highly specific and sensitive salivary measurement for testosterone by mass 
spectrometry presents the opportunity to examine health correlates of salivary testosterone (Sal-T) in a 
large-scale population survey. 
Objective 
To examine associations between Sal-T and health-related factors in men and women aged 18-74 
years. 
Design & Setting 
Morning saliva samples were obtained from participants in a cross-sectional probability sample 
survey of the general British population (‘Natsal-3’).  
Participants 
1,599 men; 2,123 women. 
Methods 
Sal-T was measured using liquid chromatography tandem mass spectrometry; linear regression was 
used to examine associations between self-reported health factors and mean Sal-T. 
Results 
In men, mean Sal-T was associated with a range of health factors after age-adjustment, with 
multivariable analysis showing a strong independent negative association with BMI. Men reporting 
cardiovascular disease or currently taking medication for depression had lower age-adjusted Sal-T. 
The decline in Sal-T with increasing age remained after adjustment for health-related factors. In 
women, Sal-T declined with increasing age, however there were no age-independent associations with 
health-related factors or specific heath conditions, with the exception of higher Sal-T in smokers.  
Conclusions 
Sal-T levels were associated, independently of age, with a range of self-reported health markers, 
particularly BMI, in men but not women. The findings support the view that there is an age-related 
decline in Sal-T in men and women, which cannot be explained by an increase in ill-health.  Our 
results demonstrate the potential of Sal-T as a convenient measure of tissue androgen exposure for 
population and clinical research. 
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Introduction 
In men, testosterone deficiency with pituitary or testicular disease (male hypogonadism) is known to 
cause a wide range of symptoms and conditions including sexual dysfunction, loss of vigour, poor 
physical performance, fractures, and low mood, which can be effectively treated with Testosterone 
Replacement Therapy (TRT).(1) However, the more general relationship between male testosterone 
levels and ill-health is less well understood. Community-based studies in men have shown 
associations between lower average serum testosterone (serum-T) and poorer health outcomes, 
including frailty, obesity, insulin resistance, cardiovascular diseases and mortality, although findings 
have not always been consistent.(2–5) It is suggested that lower testosterone levels in older men may 
contribute to these ageing-related conditions although questions remain about direction and 
causality.(3) Some studies have also cast doubt as to whether there truly is an independent age-related 
decrease in testosterone, or whether the observed decline is a biomarker of accumulated co-
morbidities.(6) Currently, whether testosterone treatment would benefit symptomatic older men with 
low testosterone remains a subject of intense debate and research.(7,8) Many of the existing studies 
have been carried out in middle-aged or older men, and the health implications of lower testosterone 
in younger men are unclear. In women, circulating concentrations of testosterone are typically around 
5-10% of those in men, with distinct age-related declines, independent of the menopause.(9,10) The 
evidence for associations between testosterone and health in women is even more equivocal than for 
men.(10–13) Furthermore, research efforts in women have been seriously hampered by inadequate 
sensitivity of serum-T measurements, due to the low concentration of testosterone and poor specificity 
of commonly-used immunoassay methods.(14)  
 
Salivary testosterone (Sal-T) is believed to represent tissue hormone levels which are unaffected by 
variations in circulating binding proteins(15) thereby providing an alternative to serum free 
testosterone (free-T), in the assessment of androgen status. In contrast to the collection of serum, 
which is invasive and expensive, collection of saliva is relatively straightforward and requires 
minimal training. We have recently demonstrated that Sal-T can be reliably and accurately measured 
by a highly sensitive and specific liquid chromatography tandem mass spectrometry (LC-MS/MS) 
method (Macdonald 2011). In a validation study comparing samples from the same individuals, we 
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found that Sal-T in adult men and women not only correlated more strongly with calculated serum 
free-T than serum total-T but was also unaffected by variations in SHBG.(16)  Fiers at al (Add ref) 
confirmed the good correlation in both men and women between Sal-T and serum free-T measured by 
equilibrium dialysis but there was a significant systematic positive bias in women, which may reflect 
the influence of salivary protein binding to the lower female concentrations of Sal-T. We have 
established age-specific reference ranges for Sal-T in British men aged 18-69 years and women aged 
18–74 years.(17) However, the physiological and behavioural correlates of Sal-T have not yet been 
explored. 
 
Using data from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3), a probability 
sample survey of British men and women, we investigated whether Sal-T is associated, independently 
of age, with demographic characteristics, lifestyle, general health, and reported health conditions.  We 
hypothesised that relationships between Sal-T and health-related factors in men would be similar to 
those previously observed with serum free-T.  To our knowledge, this is the first study to have 
examined the associations between Sal-T and health in a large community sample of men and women 
using a highly sensitive and specific assay, exploiting the theoretical and practical advantages of 
salivary measurements to the full. 
 
Methods 
Participants and procedures 
Full details of the Natsal-3 methods, including details of the saliva sample collection and testing, have 
are described elsewhere.(17–19) Briefly, Natsal-3 was a probability sample survey of 15,162 men and 
women aged 16-74 years resident in Britain. Interviews took place between September 2010 and 
August 2012 using a combination of computer-assisted personal interviewing (CAPI) and computer-
assisted self-interview (CASI) for the more sensitive questions. The response rate was 57.7%.  
 
Single morning saliva samples were self-collected from a subsample of men and women aged 18-74 
years, who did not regularly work night shifts. Altogether, 9,170 eligible participants were invited to 
provide a saliva sample: 6,515 (71.0%) agreed to do so and 4,591 samples were received by the 
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laboratory and matched to the survey data (50.1% of those invited). A total of  463 samples were 
excluded due to problems with the sample quality(17) leaving 4,128 participants (45.0% of those 
invited) with a testosterone result (1,675 men; 2,453 women). This paper examines associations 
between Sal-T and health in the general population, therefore those with clinical conditions or taking 
medication likely to affect testosterone levels were excluded from analysis: currently taking 
medication for epilepsy (15 men; 15 women) or prostate disease (43 men); treatment for ovarian, 
testicular, or pituitary condition (16 men; 23 women) or for polycystic ovaries (35 women) in the past 
year; pregnant at interview (42 women); current receipt of HRT (62 women); ever receipt of HRT 
together with having had a hysterectomy (proxy measure for having had ovaries removed; 181 
women); missing data for these questions (3 men; 15 women); resulting in 1,599 men and 2,123 
women being included in the analysis. These exclusions aimed to minimise confounding of the 
relationship between testosterone and health caused by these factors, and differ from those used to 
define the ‘healthy population’ in our previous reference range analysis, which were based on criteria 
typically used in clinical reference range studies. (17) 
 
Measures 
Health and medication questions were self-reported, and body mass index (BMI) was calculated from 
self-reported height and weight. Due to small numbers of underweight individuals (BMI<18.5), these 
participants were excluded from analysis of BMI (14 men and 44 women). Most of the health 
questions were asked in the CAPI, with the exception of depressive symptoms (past 2 weeks) which 
were assessed in the CASI using a validated two-item patient health questionnaire (PHQ-2).(20) 
Cardiac, vascular disease, or hypertension were defined as ever being given such diagnoses by a 
doctor. 
 
We previously identified seasonal variation in Sal-T, thus season of data collection was included as a 
potential confounder, defined as: winter (December, January, February), spring (March, April, May), 
summer (June, July, August), autumn (September, October, November).  
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The LC-MS/MS Sal-T assay was developed using strict validation criteria,(21) with a lower limit of 
quantification of 6.5 pmol/L. Full details of the laboratory methods, including the validation of the 
assay, have been published elsewhere.(16,17)  
  
Statistical analyses 
Statistical analyses were carried out using STATA (version 13.1) accounting for the complex survey 
design (stratification, clustering, and weighting of the sample).(22) We applied two weights: the 
survey weight corrected for unequal probability of selection and differential response (by age, sex, 
and region) to the survey itself; the additional saliva weight corrected for unequal probability of 
selection and differential response to the saliva sample. Factors found to be associated with providing 
a saliva sample included age at interview, ethnicity, self-reported general health, and sexual function; 
the saliva weighting significantly reduced these biases.(18)  
 
Descriptive statistics are presented as means (standard errors), with multivariable linear regression 
used to assess differences between groups. Throughout, we censored very high Sal-T values so that, 
for each 10-year age group stratified by sex, values above the 99th percentile were assigned a value 
equal to that of the 99th percentile. The Sal-T data for men were normally distributed, however the 
distribution for women was positively skewed and so values were transformed on the natural log scale 
for analysis. Accordingly, for men we present linear regression coefficients representing differences 
in mean testosterone in pmol/l, whereas for women we present ratios of geometric mean Sal-T 
obtained from exponentiated coefficients. Interval regression was used to assign values to the range 0 
to 6.5pmol/l for 3 men, and 0.5 (to allow log transformation) to 6.5pmol/l for 62 women with 
testosterone levels below the limit of detection (<6.5pmol/l). Age was adjusted for using both linear 
and quadratic terms to account for a non-linear relationship of testosterone with age. In our previous 
presentation of reference ranges,(17) we truncated analyses for men at age 69 as we were unable to 
calculate robust upper and lower limits based on standard deviation for older men. Here we have 
included data for the full age range of men (18-74 years) as the focus is on differences in mean Sal-T, 
rather than the upper and lower reference limits. 
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As several associations were found for men, multivariable analyses were used to determine which 
health factors were independently associated with Sal-T. Variables were grouped into a series of 
domains, in order to identify their individual contributions to the overall relationships with Sal-T after 
adjustment for earlier domains. The domains were: 1) age and season; 2) relationship status and 
children; 3) BMI and 4) general health. A fifth lifestyle domain (smoking, alcohol consumption; drug 
use) contained no significant associations (either age-adjusted or multivariable) and was therefore not 
presented in the final multivariable table. Within each domain the variables were entered into a 
forward stepwise model selection process (significance level for inclusion p<0.1) with variables 
selected from earlier domains included with certainty. The ordering of domains began with factors for 
which the evidence of association was best established (from earlier publications) or of a demographic 
nature, and then proceeded to health-related factors. In this way, any identified associations between 
Sal-T and health could be seen as robust and not explained by confounding factors in other domains. 
An equivalent analysis was not performed for women given the lack of age-adjusted associations. In 
further analysis we examined associations between specific health conditions or medical treatments 
and Sal-T, adjusting firstly for age and then for those factors that had been cumulatively selected from 
domains 1 to 3.  
 
Ethics  
The Natsal-3 study was approved by the Oxfordshire Research Ethics Committee A (reference: 
09/H0604/27). Written informed consent was obtained for anonymised testing of saliva samples, 
without return of results. 
 
Results 
Age-adjusted associations of demographic and general health factors with mean salivary testosterone 
(Table 1 & 2, figures 1 & 2) 
 
For both men and women, mean Sal-T decreased with increasing age, and seasonal variation was 
observed, as previously reported.(17) Among men, variation by relationship status was seen after 
adjustment for age (e.g. coefficient for those not in a steady relationship, compared with those 
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married/cohabiting: 20.12 (95% confidence interval: 6.41 to 33.82)); no association was found with 
having children. There were no associations with demographic factors for women. 
 
Mean Sal-T was associated, independently of age, with a range of measures of general health in men 
but not in women. In age-stratified analyses, there was a clear association between mean Sal-T and 
increasing categories of BMI (normal, overweight, obese) in men but not women (figure 1), and a 
more moderate difference by self-reported general health among men, with no association for women 
(figure 2). Expressed as age-adjusted coefficients, we found levels were lower among men who were 
overweight or obese, (coefficients -23.63 (-34.81 to -12.46) and -51.26 (-64.64 to -37.88) respectively, 
compared with normal BMI)  reported poorer general health (-16.14 (-27.50 to -4.78)), longstanding 
illness or disability (-13.36 (-27.50 to -4.78)); difficulty walking upstairs (-23.74 (-44.08 to -3.41) for 
those with much difficulty/inability, compared with no difficulty), or two or more comorbid health 
conditions (-21.57 (-35.10 to -8.04) compared with none). There was no association among men with 
smoking, alcohol consumption or illicit drug use.  
 
The only health association found for women was with smoking, with higher Sal-T among women 
who smoked (ratio of geometric means 1.11 (1.02-1.22) for current smokers compared with non-
smokers). Women who had taken hormonal contraception (HC) in the past year had lower mean Sal-T 
(Geometric mean ratio compared with those who hadn’t taken HC: 0.85 (0.77-0.94), p=0.001). 
Adjusting the women’s analysis for season as well as age did not change any of the results (data not 
shown).  A sensitivity analysis excluding women on HC in the past year (n=590) produced generally 
similar results, except for smoking, which became non-significant (p=0.110; data not shown).  
 
Multivariable analyses of men (table 3) 
In men, all associations with variables in domains 1-3 in the age-adjusted analyses remained 
significant in the multivariable analyses: age, season, relationship status, and BMI. Only one variable 
from domain 4 - self-reported general health - was selected in the model, although providing 
inconclusive evidence of an association (-11.39 (-22.69 to -0.10) p=0.048). In further exploratory 
analysis we fitted a model excluding BMI but including age, season, and relationship status,  in which 
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self-reported general health was found to be more strongly associated with Sal-T (-19.01 (-30.48 to -
7.54) p=0.001; data not shown).  
 
Specific health conditions (table 4) 
Lower mean Sal-T was associated with reported cardiovascular disease (including hypertension) in 
men, independently of age (-18.06 (-29.43 to -6.68)). There was also an association with reporting 
currently taking medication for depression (-24.56 (-48.33 to -0.79)), but not with current depressive 
symptoms. There was no association with self-reported diabetes. Further adjustment for season, 
relationship status, and BMI attenuated the association with cardiovascular disease (-8.98 (-20.27 to 
2.31); p=0.119) but strengthened the association with depression medication (-28.02 (-51.64 to -4.40); 
p=0.020). There was no evidence of associations between Sal-T and any of these conditions among 
women. 
 
Discussion 
Summary of findings and comparison with other studies 
This study is the first to show associations between salivary testosterone (Sal-T) and health in a large 
national probability sample survey of men and women, across a wide age range. In men, we found 
significant age-independent associations between lower Sal-T and higher BMI, poorer self-reported 
general health, mobility problems, longstanding illness, and comorbid conditions (cardiovascular 
disease, treatment for depression). The association between Sal-T and self-reported general health in 
men was attenuated after adjustment for BMI, suggesting that the relationship is at least partly 
explained by obesity. We found no associations between Sal-T and health factors in women, except 
smoking, with higher Sal-T among women who smoked. 
 
We showed that the age-related decline in Sal-T remains after adjusting for health and demographic 
factors. This is consistent with some previous serum studies,(3,5) although others have attributed the 
age-related decline in serum total T entirely to declining health.(6) This inconsistency may partly be 
explained by the age-related increase in sex hormone binding globulin (SHBG) which attenuated the 
age-trend in total serum-T, but not Sal-T.   
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Our findings of associations with health-related factors in men are largely consistent with evidence 
from serum studies. There is a large body of evidence that, in men, obesity is strongly associated with 
lower serum-T, independently of age.(3) Associations have also been reported between lower serum-
T and insulin resistance and diabetes, pre-clinical indicators for cardiovascular disease (CVD), 
cardiovascular events, physical frailty and increased mortality.(3,5,23,24) Cross-sectional data cannot 
shed light on the direction of these relationships but longitudinal studies have found that obesity leads 
to decreases in testosterone, and that weight loss increases testosterone levels in obese men,(25) 
although there is also evidence of bidirectional associations.(3) Longitudinal serum-T studies have 
shown that low testosterone precedes cardiovascular events.(23) The mechanisms of this association 
are unclear and may involve low testosterone affecting several cardiovascular risk factors, central 
adiposity and inflammation.(26) Unlike most serum-T studies we did not find an association with self-
reported diabetes for men, but the number of men with diabetes in our sample was small. We found 
no association with current depressive symptoms but did observe an association with reporting 
treatment for depression. Little research exists on the effects of antidepressants on the hypothalamic-
pituitary-gonadal axis, although one study has found higher salivary testosterone levels among men 
and women using Selective Serotonin Reuptake Inhibitors (SSRIs), which contrasts with our 
results.(27)   
 
We examined the associations between Sal-T and several demographic factors in order to address 
potential confounding of the associations with health. A previous study found ethnic variation in 
testosterone levels, however we were unable to examine this due to small numbers of participants in 
ethnic minority groups. The findings of this study only partly concur with those from (generally 
smaller) studies which have reported lower testosterone among men and women in established 
relationships (28) and parents, especially those actively involved in childcare(29,30).  We found 
associations with relationship status for men only, and no associations with parenthood for either men 
or women, however our measures of parenthood capture a broad range of circumstances in terms of 
children’s age and parents’ involvement in child-rearing, which may explain this apparent 
discrepancy. 
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We found no association between Sal-T and smoking, alcohol consumption, or drug use in men. 
Previous serum-T in men studies have generally, although not always consistently, shown smoking to 
be associated with increased total-T, yet few studies have shown an association with free-T.(31) 
Smoking, via direct effects on liver function, increases SHBG levels, which may explain why total-, 
but not free-, testosterone is increased in smokers.(31) The evidence regarding whether testosterone is 
associated with alcohol consumption is also mixed,(24,32) and few studies have examined 
associations with other drugs.  
 
Previous research about the health correlates of testosterone in women has not only yielded 
inconsistent findings, but has largely been carried out within narrow age ranges, and using sub-
optimal measures of testosterone.(14) We found no evidence of associations between Sal-T and 
general health indicators, or specific conditions or medications in women. We did find a positive 
association with smoking, which is consistent with other studies.(11,33) We also found lower mean 
Sal-T among women who had taken hormonal contraception in the past year, which supports evidence 
from smaller experimental studies showing increases in SHBG and corresponding decreases in serum 
free-T among women taking oral contraceptives.(34) Our findings regarding the different relationship 
with health for men and women may relate to the different sites of production, with testosterone 
coming from the adrenal glands as well as the ovaries in women, but exclusively from the testes in 
men, the menstrual cyclical fluctuations and the much lower concentrations of Sal-T in women 
compared to men. 
 
Strengths and limitations 
A key strength of this study is the highly sensitive and specific Sal-T assay, enabling accurate 
measurement in men as well as women, (albeit there is a systematic positive bias due to salivary 
protein binding among women, and permitting measurement of testosterone on a large-scale 
probability sample survey across a wide age range. Although less invasive than serum, large-scale 
home-based collection of saliva has presented a number of challenges including: coping with the 
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diurnal variation in testosterone levels, preventing contamination, ensuring prompt receipt at the 
laboratory before deterioration, and minimising non-response bias. Considerable attention was paid to 
the development of protocols for sample collection, with extensive validation and piloting,(18) yet 
although 71.0% of participants agreed to provide a sample, useable samples were received from only 
45.0% of those invited, highlighting the challenge of obtaining self-collected and self-posted samples. 
This response rate is similar to community-based serum testosterone studies,(35,36) and the response 
rate to the survey overall was similar to other major British social surveys. To minimise potential non-
response bias, both to the survey and to the saliva sample, we applied statistical weights during 
analysis.(18)  
 
The health data collected were self-reported and are therefore reliant on knowledge of conditions and 
medications, and accurate reporting. This may particularly affect BMI based on self-reported height 
and weight, as people tend to underestimate weight and overestimate height. However, previous 
studies have shown self-reported height and weight to be sufficient for examining associations in 
epidemiological studies.(37) As a sexual health survey, only a limited number of questions about 
general health could be asked, therefore we were unable to look at associations with some factors that 
may have been of interest such as frailty, osteoporosis, or sleep disturbance. We were also unable to 
measure preclinical disease indicators.  
 
Only one sample was collected from each participant and so we were unable to take into account 
intra-individual variation in testosterone levels, which may be particularly relevant for pre-
menopausal women as testosterone varies throughout the menstrual cycle.(38) However, some have 
argued that it is unnecessary to control for menstrual variation, given the relatively small effects 
compared with, for example, diurnal variation or individual differences.(38) This is consistent with 
our earlier validation work in which did not find significant within-individual differences when 
samples were taken at weekly and monthly intervals.(16) A small number of men and women (n=20 
and n=37 respectively) included in our analysis reported receiving cancer treatment in the past year, 
and as the nature of the cancer or treatment was unknown, this could have affected testosterone levels 
for some. However, given the small numbers this is unlikely to have affected our findings overall.  
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Implications for clinical research, policy, and further research need 
Our findings are broadly consistent with previous research using serum, and where differences exist it 
is not always clear whether these are due to differences in the measure used (serum total-T, free-T, or 
Sal-T), or due to other differences in the study population and design. Further observational research 
using reliable saliva T measurements  linked to a broader range of clinical correlates would strengthen 
the evidence base in this respect.  
 
There are concerns about inappropriate marketing and use of testosterone replacement therapy (TRT) 
for men, particularly in the USA.(7) Our cross-sectional finding of lower Sal-T among men with 
poorer health does not imply causality, nor indicate treatment. Although longitudinal research has 
shown that low testosterone precedes poor health outcomes(23) the benefits of TRT in the general 
population remain unclear. Further research is needed before conclusions can be reached regarding 
the nature of the relationship between testosterone and ill-health, and the risks and benefits of 
intervention. 
 
Our finding of an independent age-related decline in Sal-T suggests that reproductive senescence in 
men, as in women, is not solely the consequence of poor health. The clinical significance of this 
merits further investigation using Sal-T as well as serum-T measurements. The application of Sal-T 
measurement in future research should make a significant contribution towards clarifying the role of 
low testosterone in health and ageing in men and women  
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Table 1: Sample characteristics, mean salivary Testosterone (Sal-T), and associations between Sal-T and demographic 
and health factors: MEN 
  
Denominators (n)  
unwt, wt 
mean sal-
T (pmol/l) (SE) 
age-adjusted# 
coefficients (95% CI) 
All men 1599 1886 223.49 3.33   
 Age, season, region           
 Age group         p<0.0001 
18-24 186 242 315.81 9.14 - - 
25-34 245 328 264.62 7.77 -51.19 (-74.44, -27.94) 
35-44 236 363 234.16 8.42 -81.65 (-105.90, -57.41) 
45-54 297 388 205.74 5.11 -110.08 (-130.78, -89.37) 
55-64 330 334 174.63 4.34 -141.18 (-160.84, -121.52) 
65-74 305 231 151.72 3.74 -164.09 (-183.51, -144.68) 
Season         p=0.0360 
winter 400 500 235.15 6.93 - - 
spring 464 521 223.77 6.09 -5.75 (-20.90, 9.40) 
summer 421 457 207.52 6.02 -20.73 (-36.74, -4.72) 
autumn 314 408 226.74 6.40 -2.95 (-19.42, 13.52) 
Region         p=0.2432 
Scotland & North of England 558 639 230.52 5.74 - - 
Midlands & Wales 355 391 224.33 6.48 -7.20 (-21.22, 6.81) 
East of England & South of England 686 856 217.86 5.17 -11.08 (-24.14, 1.99) 
Relationship and children           
 Relationship status 
    
p=0.0103 
Married / civil partnership / cohabiting 928 1277 206.71 3.95 - - 
Steady relationship, not living together 187 179 263.63 8.34 14.62 (-1.89, 31.13) 
Not in a steady relationship 459 405 261.46 6.97 20.12 (6.41, 33.82) 
Any natural children         p=0.374 
No 642 736 256.27 5.99 - - 
Yes 928 1104 204.97 3.62 -5.80 (-18.61, 7.00) 
Lives with a child (aged <18y) 
    
p=0.7611 
No 1281 1342 220.84 3.76 - - 
Yes 318 544 230.05 6.18 -2.17 (-16.21, 11.86) 
BMI           
 BMI$         p<0.0001 
Normal (BMI 18.5-25 kg/m2) 599 723 253.68 5.07 - - 
Overweight (BMI 25-30 kg/m2) 612 715 209.82 4.09 -23.63 (-34.81, -12.46) 
Obese (BMI >30 kg/m2) 334 365 174.34 5.72 -51.26 (-64.64, -37.88) 
General health and function           
 Self-reported general health         p=0.0054 
Very good/good 1253 1510 232.72 3.83 - - 
Fair/bad/very bad 346 375 186.37 5.08 -16.14 (-27.50, -4.78) 
Longstanding illness or disability         p=0.0131 
No 977 1251 238.63 4.15 - - 
Yes 621 634 193.69 4.54 -13.36 (-23.91, -2.81) 
Difficulty walking upstairs because of a 
health problem         p=0.0499 
No difficulty 1369 1643 230.41 3.59 - - 
Some difficulty 166 177 182.11 7.60 -8.31 (-23.34, 6.71) 
Much difficulty or unable 64 66 162.09 12.08 -23.74 (-44.08, -3.41) 
Number of comorbid conditions*         p=0.0073 
0 913 1169 245.12 4.38 - - 
1 397 435 201.40 5.87 -11.10 (-24.18, 1.98) 
2+ 289 282 167.97 5.49 -21.57 (-35.10, -8.04) 
Lifestyle           
 Current smoker         p=0.6599 
 No 1247 1458 219.63 3.60 - - 
Yes 352 428 236.67 7.20 3.01 (-10.42, 16.45) 
Average alcohol consumption per week         p=0.3611 
 None 295 343 213.51 7.44 - - 
Not more than recommended 1130 1352 226.02 3.98 9.51 (-5.57, 24.59) 
More than recommended 167 183 223.35 9.83 14.50 (-7.32, 36.32) 
Taken non-prescribed drugs, past year         p=0.7584 
 No 1363 1585 218.03 3.52 - - 
Yes 197 244 264.34 9.03 2.89 (-15.56, 21.34) 
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Table 1 footnotes: 
#adjusted for age and age-squared to account for non-linear relationship between testosterone and age 
*Measure of comorbidity includes arthritis, heart attack, coronary heart disease, angina, other forms of heart disease, 
hypertension, stroke, diabetes, broken hip or pelvis bone or hip replacement ever, backache lasting longer than 3 months, 
any other muscle or bone disease lasting longer than 3 months, treatment for depression, treatment for cancer, and 
treatment for any thyroid condition in the past year. 
$Those with BMI<18.5 have been excluded from analysis due insufficient numbers to analyse this group separately 
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Table 2: Sample characteristics, mean salivary Testosterone (Sal-T), and associations between Sal-T and demographic 
and health factors: WOMEN 
  
 
Denominators (n)  
(unwt, wt) 
mean sal-T 
(pmol/l) (SE) 
age-adjusted 
Ratios# (95% CI) 
All 2123 1899 37.09 0.86 
  Age, season, region             
Age group         p<0.0001   
18-24 231 252 49.98 4.15 - - 
25-34 390 359 41.74 1.82 0.93 (0.78, 1.12) 
35-44 391 381 40.49 1.92 0.91 (0.76, 1.09) 
45-54 408 390 34.16 1.55 0.76 (0.63, 0.91) 
55-64 378 304 27.35 0.98 0.63 (0.53, 0.75) 
65-74 325 213 27.24 1.25 0.60 (0.50, 0.72) 
Season         p<0.0001   
winter 529 460 31.57 1.09 - - 
spring 652 556 37.71 1.95 1.15 (1.05, 1.26) 
summer 491 394 42.46 1.83 1.28 (1.16, 1.40) 
autumn 451 489 37.27 1.65 1.09 (0.98, 1.20) 
Region         p=0.2229   
Scotland & North of England 741 632 35.66 1.19 - - 
Midlands & Wales 475 408 35.09 2.19 0.96 (0.87, 1.05) 
East of England & South of England 907 859 39.10 1.32 1.04 (0.96, 1.13) 
Relationship and children             
Relationship status 
    
p=0.9109 
 Married / civil partnership / cohabiting 1203 1234 35.50 0.92 - - 
Steady relationship, not living together 257 196 42.54 2.39 1.01 (0.89, 1.14) 
Not in a steady relationship 646 449 39.75 2.08 1.02 (0.94, 1.10) 
Any natural children         p=0.6694   
No 597 520 43.25 2.25 - - 
Yes 1497 1336 34.67 0.78 1.02 (0.93, 1.12) 
Lives with a child (aged <18y) 
    
p=0.5441 
 No 1409 1179 35.80 1.15 - - 
Yes 711 717 39.09 1.29 1.03 (0.94, 1.12) 
BMI             
BMI$         p=0.7452   
Normal (BMI 18.5-25 kg/m2) 965 870 39.39 1.23 - - 
Overweight (BMI 25-30 kg/m2) 586 504 34.82 1.37 0.97 (0.89, 0.94) 
Obese (BMI >30 kg/m2) 428 355 35.13 1.53 0.97 (0.90, 0.94) 
General health and function             
Self-reported general health         p=0.3880   
Very good/good 1753 1560 37.91 0.98 - - 
Fair/bad/very bad 370 339 33.33 1.65 0.96 (0.88-1.05) 
Longstanding illness or disability         p=0.8803   
No 1360 1281 38.21 1.11 - - 
Yes 763 618 34.77 1.37 1.01 (0.92-1.10) 
Difficulty walking upstairs because of a 
health problem         p=0.4682   
No difficulty 1787 1598 38.11 0.95 - - 
Some difficulty 241 221 32.92 2.62 0.99 (0.87, 1.13) 
Much difficulty or unable 95 80 28.4 2.79 0.87 (0.69, 1.09) 
Number of comorbid conditions*         p=0.5587   
0 1177 1101 39.52 1.22 - - 
1 546 474 35.01 1.33 0.99 (0.91, 1.08) 
2+ 400 324 31.91 2.00 0.93 (0.82, 1.06) 
Lifestyle             
Current smoker         p=0.0165   
No 1714 1548 35.88 0.82 - - 
Yes 409 351 42.44 2.45 1.11 (1.02, 1.22) 
Average alcohol consumption per week         p=0.3272   
None 640 606 36.04 1.57 - - 
Not more than recommended 1280 1113 37.97 1.13 1.06 (0.98, 1.16) 
More than recommended 198 175 35.23 2.08 1.02 (0.91, 1.15) 
Taken non-prescribed drugs, past year         p=0.3064   
No 1970 1746 36.68 0.90 - - 
Yes 115 106 46.44 4.01 1.09 (0.93, 1.28) 
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Table 2 footnotes: 
unwt=unweighted; wt=weighted 
#Ratio of geometric means, obtained from exponentiated age-adjusted linear regression coefficients of log-transformed 
data for women. Adjusted for age and age-squared to account for non-linear relationship between testosterone and age 
*Measure of comorbidity includes arthritis, heart attack, coronary heart disease, angina, other forms of heart disease, 
hypertension, stroke, diabetes, broken hip or pelvis bone or hip replacement ever, backache lasting longer than 3 months, 
any other muscle or bone disease lasting longer than 3 months, treatment for depression, treatment for cancer, and 
treatment for any thyroid condition in the past year. 
$Those with BMI<18.5 have been excluded from analysis due insufficient numbers to analyse this group separately  
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Figure 1: Mean (95% Confidence Interval) Sal-T (pmol/l) by age group and BMI 
Note: figures for men and women have different scales 
a) Men 
  
b) Women 
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Figure 2: Mean (95% Confidence Interval) Sal-T (pmol/l) by age group and self-reported general health status 
Note: figures for men and women have different scales 
 
a) Men 
 
b) Women 
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Table 3: Adjusted associations between demographic and health factors and salivary Testosterone: MEN 
 
 
  
age-adjusted 
coefficients (95% CI)
Domain 1 
adjusted 
coefficients (95% CI)
Domain 2 
adjusted 
coefficients (95% CI)
Domain 3 
adjusted 
coefficients (95% CI)
Domain 4 
adjusted 
coefficients (95% CI)
Age, season, region
Age
18-24 186 242 - - - - - - - - - -
25-34 245 328 -51.19 (-74.44, -27.94) -52.08 (-75.40, -28.75) -41.05 (-65.54, -16.56) -33.70 (-58.31, -9.09) -31.90 (-56.44, -7.35)
35-44 236 363 -81.65 (-105.90, -57.41) -81.66 (-105.55, -57.78) -69.74 (-94.08, -45.39) -62.79 (-86.52, -39.07) -60.66 (-84.61, -36.71)
45-54 297 388 -110.08 (-130.78, -89.37) -109.69 (-130.35, -89.03) -97.21 (-118.62, -75.81) -82.80 (-104.26, -61.35) -79.74 (-101.33, -58.16)
55-64 330 334 -141.18 (-160.84, -121.52) -140.78 (-160.37, -121.18) -126.87 (-147.78, -105.96) -111.77 (-132.95, -90.59) -107.91 (-128.99, -86.82)
65-74 305 231 -164.09 (-183.51, -144.68) -163.73 (-183.04, -144.42) -149.80 (-170.91, -128.70) -134.69 (-155.81, -113.56) -130.48 (-151.83, -109.13)
Season
winter 400 500 - - - - - - - - - -
spring 464 521 -5.75 (-20.90, 9.40) -5.75 (-20.90, 9.40) -6.57 (-21.79, 8.66) -1.93 (-15.68, 11.81) -2.00 (-15.76, 11.75)
summer 421 457 -20.73 (-36.74, -4.72) -20.73 (-36.74, -4.72) -21.48 (-37.47, -5.49) -16.41 (-30.21, -2.61) -16.76 (-30.56, -2.96)
autumn 314 408 -2.95 (-19.42, 13.52) -2.95 (-19.42, 13.52) -2.90 (-19.44, 13.64) 1.24 (-13.03, 15.52) 1.46 (-12.79, 15.71)
Relationship and children
Relationship status
Married / civi l  partnership / cohabiting 928 1277 - - - - - - - -
Steady relationship, not l iving together 187 179 14.62 (-1.89, 31.13) 16.02 (-0.55, 32.58) 11.18 (-4.54, 26.91) 11.68 (-4.07, 27.42)
Not in a  s teady relationship 459 405 20.12 (6.41, 33.82) 20.50 (6.85, 34.15) 18.52 (5.13, 31.91) 20.10 (6.50, 33.70)
Any natural children
No 642 736 - -
Yes 928 1104 -5.80 (-18.61, 7.00)
Lives with a child (aged <18y)
No 1281 1342 - -
Yes 318 544 -2.17 (-16.21, 11.86)
BMI
BMI$
Normal  (BMI 18.5-25 kg/m2) 599 723 - - - - - -
Overweight (BMI 25-30 kg/m2) 612 715 -23.63 (-34.81, -12.46) -22.40 (-33.63, -11.17) -22.33 (-33.56, -11.11)
Obese (BMI >30 kg/m2) 334 365 -51.26 (-64.64, -37.88) -49.69 (-62.84, -36.54) -47.59 (-61.22, -33.96)
General health and function
Self-reported general health
Very good/good 1253 1510 - - - -
Fa i r/bad/very bad 346 375 -16.14 (-27.50, -4.78) -11.39 (-22.69, -0.10)
Longstanding illness or disability
No 977 1251 - -
Yes 621 634 -13.36 (-23.91, -2.81)
Difficulty walking up stairs because of a 
health problem
No di fficul ty 1369 1643 - -
Some di fficul ty 166 177 -8.31 (-23.34, 6.71)
Much di fficul ty or unable 64 66 -23.74 (-44.08, -3.41)
Number of comorbid conditions*
0 913 1169 - -
1 397 435 -11.10 (-24.18, 1.98)
2+ 289 282 -21.57 (-35.10, -8.04)
p<0.0001
p=0.0054 p=0.048
p=0.0131
p=0.0499
p=0.0073
p<0.0001 p<0.0001
p=0.0103 p=0.0073 p=0.0185 p=0.0110
p=0.374
p=0.7611
p<0.0001
p=0.0360 p=0.0360 p=0.0256 p=0.0368 p=0.0294
p<0.0001
Denominators (n)
 (unwt, wt)
p<0.0001 p<0.0001 p<0.0001
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Table 3 footnotes: 
unwt=unweighted; wt=weighted 
Variables were grouped into a hierarchy of  'domains' as follows: 1. Age, season, region; 2. Relationship status and family; 3. BMI; 4. General health and function. 'Lifestyle' factors (smoking, drinking, 
drug use' were not included in the adjusted analysis given lack of associations seen in age-adjusted analysis. 
The variables were entered in these groups in order, and including any variables found to be significant from previous domains, into forwards stepwise linear (interval) regression models to generate 
adjusted coefficients. The significance criteria for retention in the model was p<0.1.
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Table 4: Associations between reporting specific health conditions and medical treatmentsand salivary Testosterone (Sal-T) by gender 
  Men   Women 
  
Denominators 
(n) 
unwt, wt 
mean sal-
T (pmol/l) (SE) 
age-adjusted 
coefficients (95% CI) 
 
Denominators 
(n) 
unwt, wt 
mean sal-T 
(pmol/l) (SE) 
age-adjusted 
ratios# (95% CI) 
All 1599 1886 223.49 3.33     
 
2123 1899 37.09 0.86     
Any cardiac or vascular disease or 
hypertension         p=0.0019 
 
        p=0.6863 
no 1257 1548 235.47 3.75 - - 
 
1789 1625 37.99 0.95 1.00 - 
yes 342 338 168.6 4.92 -18.06 (-29.43, -6.68) 
 
334 275 31.79 1.71 0.98 (0.88, 1.09) 
Diabetes 
    
p=0.0932 
     
p=0.4689 
no 1482 1769 227.47 3.4 - - 
 
2036 1828 37.34 0.87 1.00 - 
yes 117 116 162.98 8.82 -15.55 (-33.71, 2.61) 
 
87 71 30.67 2.54 0.93 (0.77, 1.13) 
Currently taking medication for 
depression 
    
p=0.0428 
     
p=0.5670 
no 1513 1810 224.79 3.42 - - 
 
1930 1737 37.29 0.92 1.00 - 
yes 86 75 192.34 11.61 -24.56 (-48.33, -0.79) 
 
193 163 34.99 2.11 0.97 (0.86, 1.09) 
Depressive symptoms^ 
    
p=0.7057 
     
p=0.7079 
no 1386 1644 223.84 3.41 - - 
 
1864 1646 37.13 0.81 1.00 - 
yes 176 186 228.68 11.25 -4.00 (-24.77, 16.77)   222 206 38.04 3.74 0.97 (0.85, 1.12) 
 
Table 4 footnotes:  
unwt=unweighted; wt=weighted 
^Participants were asked whether they had often been bothered by feeling down, depressed, or hopeless in the past 2 weeks, and whether they had often been bothered by little interest or pleasure 
in doing things in the past 2 weeks, using a validated two-question patient health questionnaire (PHQ-2). 
#Ratio of geometric means, obtained from exponentiated age-adjusted linear regression coefficients of log-transformed data for women 
